数字中医药（英文）2018，Vol.1Issue(1)：90-101,12.
基于网络药理学探析远志散治疗痴呆的分子生物机制研究
Molecular Biological Mechanisms of Yuan Zhi Powder in the Treatment of Alzheimer's Disease: an Analysis Based on Network Pharmacology
摘要
Abstract
Objective To predict the main active ingredients, potential targets and molecular mechanisms of Yuan Zhi powder in treatment of dementia by using network pharmacology. Methods A database of chemical constituents of Yuan Zhi powder was constructed by using databases and literatures. Potential targets were predicted by reverse molecular docking, and then a component-target network was constructed. The target network of Alzheimer's disease (AD) was mapped and analyzed to obtain the "active ingredient-AD target" network. The key targets were screened through network analysis. Finally, the rationality of the prediction was analyzed by comparing with the target reported in the literatures. Results There were 180 chemical constituents acting on the AD target, and the targets included three key targets (cyclooxygenase-2, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M2) and an important target (acetylcholine esterase). Alzheimer's disease may be treated by regulating the activity of acetylcholine receptors and the binding to β-amyloid protein, and its biological process may be concentrated in the acetylcholine receptor signal pathway, negative regulation of synaptic transmission and so on. Conclusion The fact that Yuan Zhi powder can treat AD is consistent with the characteristics of multi-components-multitargets- multiple pathways of traditional Chinese medicine. The important targets obtained from network analysis have a large proportion in literature research, so network analysis have some rationality.关键词
远志散/网络药理学/有效成分-AD靶标网络/网络分析/痴呆Key words
Yuan Zhi powder/Network pharmacology/Active ingredients–AD targets network/Network analysis/Dementia引用本文复制引用
强伟杰,李琦,王娅杰,朱晓新,陈颖,贺福元,肖美凤,蔡维艳,戴逸飞,杨庆,李玉洁,翁小刚..基于网络药理学探析远志散治疗痴呆的分子生物机制研究[J].数字中医药（英文）,2018,1(1):90-101,12.基金项目
We thank for the funding support from the Major new drug creation project (2017ZX09101002-002-008), National Natural Science Foundation of China (81403171) and Autonomous Program of China Academy of Chinese Medical Sciences (QZPT001 and 2014065). （2017ZX09101002-002-008）
